CD55 / DAF (Protein | Antibody | cDNA Clone | ELISA Kit)

All CD55 / DAF reagents are produced in house and quality controlled, including 21 CD55 / DAF Antibody, 3 CD55 / DAF ELISA, 39 CD55 / DAF Gene, 1 CD55 / DAF IP Kit, 4 CD55 / DAF Lysate, 4 CD55 / DAF Protein, 3 CD55 / DAF qPCR. All CD55 / DAF reagents are ready to use.

CD55 / DAF Background

CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 3 SCRs (short consensus repeats) in their plasma-exposed regions. It is a major regulator of the alternative and classical pathways of complement activation and is expressed on all serum-exposed cells. CD55 is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. DAF seems to exert different functions beyond its immunological role such as promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility. It is commonly hijacked by invading pathogens, including many enteroviruses and uropathogenic Escherichia coli, to promote cellular attachment prior to infection. This 7-75 kDa glycoprotein CD55 containing four SCR modules is involved in the regulation of the complement cascade. It inhibits complement activation by suppressing the function of C3/C5 convertases, thereby limiting local generation or deposition of C3a/C5a and membrane attack complex (MAC or C5b-9) production. DAF has been identified as a ligand for an activation-associated, seven-transmembrane lymphocyte receptor, CD97, which is a receptor mediating attachment and infection of several viruses and bacteria. In addition, it has been shown that DAF regulates the interplay between complement and T cell immunity in vivo, and thus may be implicated in immune and tumor biology.

CD55 / DAF References

  • Lea S. (2002) Interactions of CD55 with non-complement ligands. Biochem Soc Trans. 30(Pt 6): 1014-9.
  • Mikesch JH, et al. (2006) The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol. 28(5-6): 223-32.
  • Wang Y, et al. (2010) Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury. J Neuroinflammation. 7:24.
彩票大奖得主捐赠 江苏快三app最新版 湖北快3历史开奖查询 安徽11选5今天开奖结果查询 吉林快3群98群 贵州11选5软件下载 河北体彩11选五中奖 甘肃十一选五推荐号码 东方6加1大奖排行 炒股配资平台哪家好 吉林快三开奖结果查询